Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.

The Journal of clinical investigation - 1 Dec 2007

Gao Sizhi Paul, Mark Kevin G, Leslie Kenneth, Pao William, Motoi Noriko, Gerald William L, Travis William D, Bornmann William, Veach Darren, Clarkson Bayard, Bromberg Jacqueline F

Abstract excerpt

Persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas. pSTAT3 is found in primary adenocarcinomas and cell lines harboring somatic-activating mutations in the tyrosine kinase domain of EGFR. Treatment of cell lines with either an EGFR inhibitor or an src kinase inhibitor had no effect on pSTAT3 levels, whereas a pan-JAK inhibitor (P6) blocked activation of STAT3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Receptor gp130
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-6

Share to Janus Kinases

Share to Mice, Nude

Share to Neoplasm Transplantation

Share to RNA, Small Interfering

Share to STAT3 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 18060032
DOI: 10.1172/JCI31871
PMCID: PMC2096430

Genes

EGFR
STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.PMID 18060032Read ↗

EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.Semantic proximity Read ↗

Autocrine IL-6 signaling: a key event in tumorigenesis?Semantic proximity Read ↗

Targeting the Interleukin-6/Jak/Stat Pathway in Human MalignanciesSemantic proximity Read ↗

Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer.Semantic proximity Read ↗

IL-6 involvement in epithelial cancers.Semantic proximity Read ↗

The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.Semantic proximity Read ↗

Role of STAT3 in lung cancerSemantic proximity Read ↗

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.Semantic proximity Read ↗

JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.Semantic proximity Read ↗

STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.Semantic proximity Read ↗

Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma.Semantic proximity Read ↗

IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.